XNASTMCI
Market cap498mUSD
Jan 15, Last price
8.47USD
1D
-4.19%
1Q
49.16%
IPO
-72.32%
Name
Treace Medical Concepts Inc
Chart & Performance
P/E
—
P/S
2.82
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
187m
+31.92%
Net income
-50m
L+4.71%
CFO
-35m
L+12.81%
Earnings
Feb 25, 2025
Profile
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 187,118 31.92% | 141,838 50.22% | |||
Cost of revenue | 238,546 | 176,682 | |||
Unusual Expense (Income) | |||||
NOPBT | (51,428) | (34,844) | |||
NOPBT Margin | |||||
Operating Taxes | 4,483 | ||||
Tax Rate | |||||
NOPAT | (51,428) | (39,327) | |||
Net income | (49,527) 4.71% | (47,298) 92.17% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 107,527 | 2,187 | |||
BB yield | -13.86% | -0.17% | |||
| Debt | |||||
Debt current | 1,404 | 339 | |||
Long-term debt | 84,790 | 84,128 | |||
Deferred revenue | |||||
Other long-term liabilities | 37 | ||||
Net debt | (37,004) | 3,215 | |||
| Cash flow | |||||
Cash from operating activities | (34,575) | (30,648) | |||
CAPEX | (11,458) | (14,838) | |||
Cash from investing activities | (81,299) | (76,518) | |||
Cash from financing activities | 109,383 | 20,806 | |||
FCF | (66,802) | (70,269) | |||
| Balance | |||||
Cash | 123,198 | 81,252 | |||
Long term investments | |||||
Excess cash | 113,842 | 74,160 | |||
Stockholders' equity | (134,022) | (84,692) | |||
Invested Capital | 342,300 | 213,810 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 60,852 | 55,277 | |||
Price | 12.75 -44.54% | 22.99 23.34% | |||
Market cap | 775,865 -38.95% | 1,270,814 25.83% | |||
EV | 738,861 | 1,274,029 | |||
EBITDA | (46,076) | (32,711) | |||
EV/EBITDA | |||||
Interest | 5,167 | 4,398 | |||
Interest/NOPBT | |||||